Article

FTC Weighs Merger's Impact on Specialty Drugs

Medco Health Solutions

MHS

+0.22%

Express Scripts

ESRX

-0.20%

The Federal Trade Commission is taking a hard look at whether the proposed $29 billion merger of prescription-drug benefit managers Inc. and Inc. would impede patients' access to expensive drugs used to treat cancer and certain other life-threatening diseases.

FTC commissioners, including Chairman Jon Leibowitz, have asked many questions about the market for the so-called specialty drugs in meetings with industry groups and others, according to people who have attended the meetings. The questions have involved the relationship between PBMs, which administer prescription-drug coverage for employers and insurers, and the manufacturers of the drugs, these people said.

Read the full story: http://hcp.lv/HkWV2o

Source: The Wall Street Journal

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Sundar Jagannath
Michael Hassett, MD, MPH, Dana-Farber Cancer Institute
Senator Vincent Polistina (R, New Jersey)
Rebecca Chacko, MD.
1 expert in this video
Rebecca Chacko, MD, breast medical oncologist at Henry Ford
Amir Fathi, MD, Mass General
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo